Fulcrum Therapeutics reported a Q4 net loss of USD 20.3 million and a FY 2025 net loss of USD 74.9 million. Q4 R&D expenses were USD 15.4 million (up 31.6%) and Q4 G&A expenses were USD 7.3 million. For FY 2025, R&D expenses were USD 56.1 million and G&A expenses were USD 28.7 million. Fulcrum Therapeutics reported no collaboration revenue in Q4 and FY 2025, following USD 80.0 million in FY 2024. Fulcrum Therapeutics ended 2025 with USD 352.3 million in cash, cash equivalents and marketable securities and said its cash runway extends into 2029. Business updates included positive 12-week results from the 20 mg cohort (n=12) in the Phase 1b PIONEER trial of pociredir in sickle cell disease, with mean absolute fetal hemoglobin increasing by 12.2% from 7.1% at baseline to 19.3% at Week 12, along with improvements in markers of hemolysis and anemia and encouraging trends in vaso-occlusive crisis reduction. The company said pociredir remained generally well-tolerated with no treatment-related serious adverse events reported through the December 23, 2025 data cutoff, and it plans to initiate a potential registration-enabling trial in H2 2026, pending FDA feedback. Fulcrum Therapeutics also said it raised USD 164.2 million in net proceeds from a December 2025 public offering and decided not to advance its bone marrow failure syndromes program into clinical development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240701PRIMZONEFULLFEED9659604) on February 24, 2026, and is solely responsible for the information contained therein.
Comments